MedTrace Logo

Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis

NCT01115426 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-05-04

No results posted yet for this study

Summary

This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.

Conditions

  • IGA Glomerulonephritis

Interventions

DRUG

Ramipril or losartan

Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.

Sponsors & Collaborators

  • University Magna Graecia

    lead OTHER

Principal Investigators

  • Giorgio Fuiano, Professor · "Magna Graecia" University of Catanzaro, Nephrology Unit

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-01-31
Primary Completion
2007-01-31
Completion
2008-01-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01115426 on ClinicalTrials.gov